Independent directory Public ClinicalTrials.gov records United States
Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 4,578 matching trials from the local directory fallback.
Conditions
Multiple Myeloma, Plasma Cell Disorder
Interventions
HDP-101
Drug
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia • Louisville, Kentucky • Omaha, Nebraska + 2 more
Conditions
Corneal Neovascularization
Interventions
10 minute photoactivation of riboflavin 0.1%, 30 minute photoactivation of riboflavin 0.1%
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Acute Myeloid Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Dexrazoxane Hydrochloride, Etoposide, Fludeoxyglucose F-18, Gemtuzumab Ozogamicin, Gilteritinib Fumarate, Liposome-encapsulated Daunorubicin-Cytarabine, Magnetic Resonance Imaging, Methotrexate, Mitoxantrone Hydrochloride, Positron Emission Tomography, Questionnaire Administration, Therapeutic Hydrocortisone
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
6 Months to 21 Years
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 143 more
Conditions
Adenocarcinoma of Lung, Lung Cancer
Interventions
Cisplatin/pemetrexed or Carboplatin/pemetrexed, Durvalumab 1500 mg IV, Oral Restorative Microbiota Therapy (RMT) Capsules, Placebo
Drug · Other
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
Phoenix, Arizona • Brainerd, Minnesota • Deer River, Minnesota + 7 more
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Assessing Pulmonary Changes in HSCT

NCT07823036
Conditions
Gas Exchange Impairment, HSCT, Respiratory
Interventions
Hyperpolarized 129 Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years and older
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Depression, Postpartum, Peripartum Depression, Post-Natal Depression, Post-partum Depression, Postnatal Depression, Postpartum Depression (PPD)
Interventions
LPCN 1154A, Placebo
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
15 Years to 45 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
16
States / cities
Tucson, Arizona • Canoga Park, California • Walnut Creek, California + 13 more
Conditions
Wet Age Related Macular Degeneration
Interventions
NT-101 ophthalmic solution, Placebo
Drug
Lead sponsor
NexThera Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Bonita Springs, Florida • Tulsa, Oklahoma • Erie, Pennsylvania
Conditions
Chronic Weight Management, Obesity, Overweight
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
3,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Conditions
Chronic Weight Management, Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions
ASC30 tablets A1, Placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years and older
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
84
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 80 more
Conditions
Healthy Participants
Interventions
Elecoglipron Reference Formulation Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose A, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Conditions
Chronic Insomnia, Chronic Insomnia Disorder, Insomnia, Insomnia Disorder
Interventions
Diphenhydramine, 25 mg, Diphenhydramine, 50 mg, Doxepin, 3 mg, Doxepin, 6 mg, Melatonin IR, 3 mg, Melatonin IR, 5 mg, Placebo, Sleep Hygiene Education, Trazodone, 100 mg, Trazodone, 50 mg, Zolpidem, 10 mg, Zolpidem, 5 mg
Drug · Dietary Supplement · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
ARDS (Acute Respiratory Distress Syndrome)
Interventions
HT31-1, Saline (0.9%, sterile, for infusion)
Drug · Other
Lead sponsor
HTIC, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Relapsed or Refractory Follicular Lymphoma
Interventions
[18F]Fluoropropyl-Trimethoprim, huCART19-IL18-eDHFR cells
Drug · Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2042
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Urticaria Chronic
Interventions
0.5 mg epinephrine, 1 mg epinephrine, Placebo
Drug
Lead sponsor
ARS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glenview, Illinois • Cincinnati, Ohio
Conditions
Alcohol Use Disorder
Interventions
PT150, Stress-Induction, alcohol
Drug · Behavioral
Lead sponsor
Pop Test Oncology LLC
Industry
Eligibility
21 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Advanced Solid Tumor, Malignant Mesothelioma, Metastatic Malignant Solid Tumor
Interventions
ISM6331
Drug
Lead sponsor
InSilico Medicine Hong Kong Limited
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
6
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio + 3 more
Conditions
Triple Negative Breast Cancer
Interventions
INBRX-106, Pembrolizumab
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Los Angeles, California • Portland, Oregon
Conditions
Multiple Myeloma, Plasma Cell Myeloma
Interventions
Fludeoxyglucose F-18, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI), Zirconium Zr 89-DFO-YS5
Other · Procedure · Drug
Lead sponsor
Robert Flavell, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Metabolic Disorders, Non-malignant Disorders
Interventions
GVHD Regimen A: UCB Recipients, GVHD Regimen B: BM Recipients, Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 20 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 20 more
Conditions
Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer, Radiation Therapy
Interventions
18F-Flurpiridaz, Coronary CT Angiography (CCTA), PET/CT 18F-Flurpiridaz Rest/Stress Test
Drug · Device · Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Recruiting Not applicable Interventional Accepts healthy volunteers

Almonds, Gut Microbiome and Kids

NCT07636850
Conditions
Cardiometabolic Health Indicators, Dysbiosis
Interventions
Cadbury Milk Chocolate Spread, Creamy Richards 100% Almonds! Creamy Natural Almond Butter
Other
Lead sponsor
Florida State University
Other
Eligibility
6 Years to 13 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Conditions
Head and Neck Cancer, Lung Cancer, Metastatic Head and Neck Cancer, Metastatic Lung Cancer, Metastatic Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Resectable Head and Neck Squamous-cell Carcinoma
Interventions
PD-1 inhibitor monotherapy - 2 cycles after 3 PM, PD-1 inhibitor monotherapy - 2 cycles before 12:00PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles after 3 PM, PD-1/PD-L1 inhibitor monotherapy - 4 cycles before 12:00PM
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Primary Biliary Cholangitis
Interventions
Placebo, Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lakewood Rch, Florida
Conditions
Type II Diabetes Mellitus
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 28 more